The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.
Stephanie Trexler, PharmD, BCOP
Advertisement
Articles by Stephanie Trexler, PharmD, BCOP
Advertisement
Latest Updated Articles
Use of Lutetium Lu-177 Vipivotide Tetraxetan to Treat Metastatic Castration-Resistant Prostate CancerPublished: October 17th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Current and Emerging BCMAxCD3 Bispecifics
3
Same Pathway, Different Profiles: Clinical Considerations for Alpelisib, Capivasertib, and Inavolisib
4
Evolocumab Reduces Risk of Major Events in Patients Without Prior Cardiovascular History
5
